Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO), a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HbA1c), weight loss, blood pressure reduction and improvements in beta-cell functioning.

Participants in the study were randomized to receive liraglutide (1.8 mg or 1.2 mg dose) or placebo for 26 weeks in addition to metformin and rosiglitazone. Treatment with liraglutide in addition to metformin and rosiglitazone resulted in a mean reduction of 1.5% from baseline HbA1c. Fasting blood glucose levels decreased by 2.4 mmol/L within two weeks on 1.8 mg of liraglutide. More than half of the patients who received liraglutide reached the American Diabetes Association HbA1c target of <7.0% compared to 28% of those who received placebo. Likewise, more than 35% of the patients in the liraglutide groups reached HbA1c < or = 6.5% compared to 14% in the placebo group. In both cases, the difference between the groups receiving liraglutide and the group treated with metformin and rosiglitazone alone was statistically significant.

In addition to improved glucose lowering, liraglutide treatment also led to significant weight loss. Mean body weight decreased significantly for liraglutide compared to an increase in weight of 0.6 kg in the metformin and rosiglitazone only group. Weight is a common problem among individuals with type 2 diabetes and is one of the most challenging aspects in managing this condition.
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... 27, 2015  The Academy of Managed Care ... Administration,s (FDA,s) draft guidance and proposed rule that ... to bear a nonproprietary name with an FDA-designated ... a decision from the FDA on the naming ... stakeholders urging the agency to use the same ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... CHARENTON-LE-PONT, France , July 13, 2010 ... its,commitment not to create any dilution for existing shareholders. The two-part,transaction was ... were cancelled to offset the dilutive impact of the, ... granted, to employees., - ...
... NEW YORK , July 12 DrChrono.com , the premier ... world-renowned iPad EMR app , featuring the ability to build macros and customizable ... DrChrono.com and its iPad EMR ... Wall Street Journal , Newsday , The Health ...
Cached Medicine Technology:Essilor Cancels Four Million Shares 2DrChrono.com iPad EMR Introduces Macros, Customizable SOAP Notes 2DrChrono.com iPad EMR Introduces Macros, Customizable SOAP Notes 3DrChrono.com iPad EMR Introduces Macros, Customizable SOAP Notes 4
(Date:8/28/2015)... ... ... Rio Salado College joined nine educational institutions in Washington D.C., July ... - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the Bill ... hosted by EDUCAUSE and NGLC, which is designed to bring leadership teams of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... ... alcohol abuse, or those who might personally be struggling with chemical dependency, may ... post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction located ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Harbor Laboratory (CSHL) has demonstrated for the first time ... can initiate signaling that regulates both the structure and ... suggests a significant role for this class of receptors ... but also in cognition and in pathological processes in ...
... strike small percentage of patients , , WEDNESDAY, June 18 ... new side effect associated with the cancer drug Gleevec ... leukemia and gastrointestinal stromal tumors. , In a letter ... New England Journal of Medicine , the doctors describe ...
... Controlling heart rate is key when heart failure, irregular ... News) -- When added to heart failure, the irregular ... , Now, an international study shows that a ... best first option for keeping patients healthy under these ...
... HILL, N.C., June 18 A CI head once ... have it, but the only,time you realize you need ... In today,s marketing space, most companies need competitive,intelligence to ... the key insights are lacking that people begin to ...
... Prevent Skin Cancer, HOUSTON, June 18 Now that ... us, the cancer care experts at Texas Oncology remind,Texans to ... Although the most prevalent cancer in the United States today,skin ... more than 1,million annual U.S. cases of skin cancer are ...
... List from a ... Worldwide Field of 5,000, PHILADELPHIA, June ... of SCA Personal Care, from among,5,000 companies for inclusion in its ... think-tank dedicated to the research and,promotion of profitable best practices in ...
Cached Medicine News:Health News:Neuroscientists show insulin receptor signaling regulates structure of brain circuits 2Health News:Neuroscientists show insulin receptor signaling regulates structure of brain circuits 3Health News:Cancer Drug Gleevec Linked to Muscle Damage 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 2Health News:Cardiologists Spot Best Treatment for a Deadly Duo 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2Health News:Texas Oncology Urges Texans to 'Save Your Skin' 2Health News:Texas Oncology Urges Texans to 'Save Your Skin' 3Health News:Ethisphere Institute Names SCA to List of Top Ethical Companies 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
Medicine Products: